Want to see NRIX full AI Analyst Report?
Top Page
Nurix Therapeutics
(NASDAQ:NRIX)
Select Model
Select Model
Rating:59Neutral
Price Target:
$26.00
▲(48.49% Upside)
Action:Reiterated
Date:07/10/26
The score is held back primarily by weak financial performance (shrinking revenue, widening losses, and substantial cash burn), partially offset by a strong technical uptrend and highly favorable corporate developments (Roche partnership and encouraging clinical data). Valuation remains constrained by negative earnings and no stated dividend support.
Positive Factors
Strategic Roche collaboration
The global Roche license and co-development/co-commercialization agreement provides a $700M upfront and up to $2.3B in payments, materially extending runway. Roche’s global infrastructure and cost-sharing reduce Nurix’s execution and commercialization burden, accelerating pivotal programs and lowering funding risk.
Negative Factors
High persistent cash burn
Sustained negative operating and free cash flow at scale signals ongoing reliance on external funding or milestone receipts. This persistent burn increases dilution and constrains strategic optionality, making program pacing and capital allocation sensitive to partner payments and financing markets.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic Roche collaboration
The global Roche license and co-development/co-commercialization agreement provides a $700M upfront and up to $2.3B in payments, materially extending runway. Roche’s global infrastructure and cost-sharing reduce Nurix’s execution and commercialization burden, accelerating pivotal programs and lowering funding risk.
Read all positive factors
Nurix Therapeutics Key Performance Indicators (KPIs)
Any
Revenue by Segment
Breaks down revenue by different business segments, highlighting which areas are driving growth and which may need strategic adjustments. This insight helps assess the company's diversification and focus.
Breaks down revenue by different business segments, highlighting which areas are driving growth and which may need strategic adjustments. This insight helps assess the company's diversification and focus.
Data provided by:
The Fly
The FlyNurix Therapeutics (NRIX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.40B
Dividend YieldN/A
Average Volume (3M)2.96M
Price to Earnings (P/E)―
Beta (1Y)1.35
Revenue Growth-58.40%
EPS Growth-31.99%
CountryUS
Employees317
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-3.45
Shares Outstanding103,781,685
10 Day Avg. Volume1,215,471
30 Day Avg. Volume2,962,288
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)2.72
Price to Sales (P/S)17.45
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue40.02
Enterprise Value/Gross Profit-24.18
Enterprise Value/Ebitda-4.60
Forecast
1Y Price Target
$34.17Price Target Upside95.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.34
Revenue Forecast (FY)$55.71M
Nurix Therapeutics Business Overview & Revenue Model
Company Description
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. T...
How the Company Makes Money
Nurix makes money primarily through (1) collaboration and licensing arrangements with larger pharmaceutical companies and (2) to a lesser extent, other operating revenue tied to those collaborations; it does not have meaningful commercial product ...
Nurix Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
26
Negative
| Breakdown | TTM | Nov 2025 | Nov 2024 | Nov 2023 | Nov 2022 | Nov 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 36.77M | 83.98M | 54.55M | 76.99M | 38.63M | 29.75M |
| Gross Profit | -60.85M | 65.12M | -167.08M | -112.16M | -145.87M | -86.68M |
| EBITDA | -319.73M | -244.84M | -185.28M | -137.81M | -176.21M | -115.07M |
| Net Income | -341.35M | -264.46M | -193.57M | -143.95M | -180.36M | -117.19M |
Balance Sheet | ||||||
| Total Assets | 535.54M | 688.13M | 669.34M | 355.60M | 416.76M | 476.77M |
| Cash, Cash Equivalents and Short-Term Investments | 443.53M | 592.94M | 609.58M | 287.91M | 309.14M | 295.72M |
| Total Debt | 58.14M | 55.73M | 28.30M | 30.61M | 11.96M | 13.04M |
| Total Liabilities | 132.91M | 149.39M | 142.35M | 155.10M | 113.06M | 134.47M |
| Stockholders Equity | 402.63M | 538.75M | 526.99M | 200.49M | 303.70M | 342.30M |
Cash Flow | ||||||
| Free Cash Flow | -304.53M | -263.47M | -181.86M | -89.77M | -172.05M | -90.03M |
| Operating Cash Flow | -293.70M | -249.47M | -172.58M | -81.36M | -159.81M | -84.36M |
| Investing Cash Flow | 19.99M | 147.85M | -257.71M | 68.30M | 27.20M | -108.25M |
| Financing Cash Flow | 257.20M | 238.64M | 485.67M | 3.22M | 117.19M | 153.88M |
Nurix Therapeutics Technical Analysis
Positive
17.51
Price Trends
18.91
Positive
17.41
Positive
16.40
Positive
Market Momentum
1.41
Positive
61.35
Neutral
54.91
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRIX, the sentiment is Positive. The current price of 17.51 is below the 20-day moving average (MA) of 22.60, below the 50-day MA of 18.91, and above the 200-day MA of 16.40, indicating a bullish trend. The MACD of 1.41 indicates Positive momentum. The RSI at 61.35 is Neutral, neither overbought nor oversold. The STOCH value of 54.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NRIX.
Nurix Therapeutics Risk Analysis
Nurix Therapeutics disclosed 81 risk factors in its most recent earnings report. Nurix Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Nurix Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $2.40B | -6.70 | -64.21% | ― | -58.40% | -31.99% | |
58 Neutral | $1.59B | -3.01 | -53.31% | ― | 213.96% | 25.74% | |
52 Neutral | $4.34B | ― | -43.94% | ― | 39.04% | 29.88% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $516.81M | -2.46 | -44.39% | ― | -79.06% | -397.92% |
* Healthcare Sector Average
NRIX
Nurix Therapeutics
23.12
11.87
105.51%
ARVN
Arvinas Holding Company
8.01
0.49
6.52%
VIR
Vir Biotechnology
9.43
3.91
70.83%
RLAY
Relay Therapeutics
19.91
16.28
448.48%
Nurix Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Nurix Highlights Promising Phase 1b Data for Bexobrutideg
Positive
Jun 11, 2026
On June 11, 2026, Nurix Therapeutics reported updated Phase 1a/1b clinical data for its oral BTK degrader bexobrutideg (NX-5948) in patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma, coinciding with a...
Business Operations and StrategyPrivate Placements and Financing
Nurix and Roche forge global BTK degrader alliance
Positive
Jun 8, 2026
On June 6, 2026, Nurix Therapeutics entered a global license and collaboration agreement with Roche to develop, manufacture and commercialize bexobrutideg, its investigational oral BTK degrader, with co-development and co-commercialization in the ...
Executive/Board ChangesShareholder Meetings
Nurix Therapeutics Shareholders Back Directors and Governance Proposals
Positive
May 15, 2026
On May 15, 2026, Nurix Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders via live webcast, with approximately 80.98% of eligible voting power represented, ensuring a quorum for corporate decision-making. Stockholders voted on directo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.